Therefore, we generated K562R, a TKI-resistant CML cell line without mutations in the BCR-ABL kinase domain (Additional file 1: Fig. S1A-D and Additional file 1: Fig. S2) and then analyzed gene expression in TKI-sensitive K562S cells, K562R cells, and K562R cells treated with imatinib; both microarray and RNA-sequencing (RNA-seq) analyses were conducted, to eliminate false positives due to analytical methods. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.